Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of OP-2024 in advanced Parkinson's disease
jRCT2021240047Phase 3Active, not recruiting
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of XI Ning in Parkinson's disease (PD) (2 arms), sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoint: Change in OFF time based on patient diary. Started Mar 2025; status: active, not recruiting.
02
Drugs
XI Ning
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2021240047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240047.